iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3FY23 Review: Gland Pharma: Earnings downgrade, limited visibility on near-term growth

24 Jan 2023 , 02:13 PM

Gland Pharma Q3 Ebitda was 17% below consensus estimates (in-line with IIFLe), as revenue was again impacted (down 10% QoQ) by component shortages (Heparin stoppers) and inventory correction this time for Enoxaparin in the US. After seeing inventory normalization in Micafungin in H1FY23, Gland’s US sales in Q3 (down USD14mn QoQ) was impacted by muted Enoxaparin sales of USD5mn in Q3 vs USD36mn in 1H. Although mgmt expects US Enoxaparin sales to sustain at USD50mn annual run-rate (vs pre-Covid run-rate of USD20- 25mn), the high-base of H1FY23 will present tough comparables for H1FY24, thereby driving muted performance for the next 2-3 quarters.

With component shortages and Enoxaparin supplies expected to normalize only gradually over the next 1-2 quarters, near-term pain for Gland is likely to continue especially given the higher competitive intensity in recent new product launches. Analysts of IIFL Securities further downgrade FY24/25 EPS by 6-7%, after having already cutting the estimates by 14-15% since Cenexi acquisition.

Analysts at IIFL Securities, believe Gland’s GM improvement of 350bps QoQ (ex-inventory write-offs in Q2) was driven by muted Enoxaparin sales, as Enoxaparin is likely a lower GM product. As Enoxaparin normalizes, they expect GMs to again moderate to 52% in FY24/25. However with operating leverage on other expenses led by RoW, they expect Ebitda margins to sustain at 30-31%.

Analysts at IIFL Securities maintain reduce rating on Gland Pharma at target price of Rs 1300.

Related Tags

  • Gland Pharma
  • Gland Pharma Q3
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.